

**ONLINE SUPPLEMENT****Porcine-Derived Pancreatic Enzyme Replacement Therapy May Be Linked to Chronic  
Hepatitis E Virus Infection in Cystic Fibrosis Lung Transplant Recipients**

5

Christina S. Thornton MD, Barbara J. Waddell BSc, Stephen E. Congly MD, Julianna Svishchuk  
BSc, Ranjani Somayaji MD, Linda Fatovich MN, Debra Isaac MD, Karen Doucette MD, Kevin  
Fonseca PhD, Steven J. Drews PhD, Jamie Borlang MSc, Carla Osiowy PhD, and Michael D.

Parkins MD

10

1

**SUPPLEMENTARY METHODS:****Hepatitis E Serological Testing of Cohorts**

Patient serum was collected in 5 ml vacutainers and processed using standard protocols by Alberta Precision Laboratories clinical staff.

15

**HEV Serological Testing - ELISA Details**

HEV IgG and IgM were assessed from CF transplant recipients at the Canadian National Microbiology Laboratory using an ELISA assay from Wantai Biopharm (Beijing, China) as part of their clinical care. From the non-transplant CF prospectively enrolled research cohort, all samples were screened first with the Abbexa Ca. ABX364866 ELISA assay, following manufacturer's instructions. Samples that were positive were confirmed with the Elabscience Biotechnology Ca. E-HD-E055 ELISA assay, following manufacturer's instructions to ensure seropositivity rates were not overestimated.

25 **Extraction of RNA from PERT**

In order to mitigate the interference of the enteric coating present in most formulations of PERT, capsules were dissolved in 1 to 3 ml of 2% sodium bicarbonate at room temperature for up to 1 hour [1] supplemented with 2 µl RNaseOut (Life Technologies Ca 10777019) and a spiked exogenous positive control [Calf Guard dissolved in 1mL PBS; 5ul Bovine Coronavirus (BCoV)]. Once dissolved, PERT samples were aliquoted into 0.5 ml aliquots. TRIzol™ was used to better purify RNA from the exceedingly protein rich, enzymatically active PERT matrix, and to mitigate the effects of enteric coating. One milliliter of TRIzol™ was mixed with dissolved aliquots as per the TRIzol™ reagent instruction for RNA purification by vortexing for

30

15 seconds followed by the addition of 200  $\mu$ l Chloroform and vortexed for 15 seconds. Samples  
35 were then centrifuged for 10 min at 14000 rpm. The aqueous phase was carefully pipetted into  
another 200  $\mu$ l chloroform, mixed well and centrifuged for 10 min at 14000 rpm. The aqueous  
phase was extracted and added to 500  $\mu$ l of 100% EtOH followed by incubation at room  
temperature for 5 minutes. Each of the aliquots derived from the same PERT capsule were  
pooled and then processed using QIAamp MinElute Virus spin (Qiagen Ca. 57705) columns with  
40 1 column for each 1 ml of dissolved sample. Columns were rinsed with AW1 buffer and 80  $\mu$ l of  
Turbo DNase (Life Technologies Ca. AM2238) (10  $\mu$ l enzyme 2U/  $\mu$ l, in 70  $\mu$ l buffer) was  
added to the column and incubated at room temperature for 15 minutes. Columns were washed  
again with 500  $\mu$ l AW1 buffer followed by 700  $\mu$ l AW2 and 700  $\mu$ l of 100% EtOH, then dried  
and eluted in 50  $\mu$ l Ultra-Pure water (Life Technologies). All samples were run alongside  
45 negative controls of 2% sodium bicarbonate buffer, 2  $\mu$ l RNaseOut, and 5  $\mu$ l Calf Guard with  
reagents only.

### **HEV Quantification by RTqPCR and RTdPCR**

One step RTqPCR was performed in duplicate using 5  $\mu$ l of extracted samples with Taqman Fast  
50 virus 1-step master mix (Life Technologies Ca. 4444432), 250 nM primers and 200 nM probe as  
described previously [2] in a final volume of 20  $\mu$ l to amplify the *orf3* target sequence. Serial  
dilutions from  $5 \times 10^6$  to 0.5 GC of a gBlock (IDT) modified from Salvio *et al* (2) were used for  
the standard curve. Each run included standard negative controls and extraction negative  
controls. RTqPCR thermal cycle conditions for the master mix were as follows and performed on  
55 the QuantStudio5 (Applied Biosystems): Reverse transcription 50°C for 5 minutes, then 95°C for  
20 seconds, followed by 45 cycles of 95°C for 3 seconds and 60°C for 30 seconds. Data was

analysed on the QuantStudio Design & Analysis Software version 1.5.2. Samples within a threshold of  $\leq 42$  cycling times were considered positive. Owing to the very high rates of PCR inhibitors in porcine-derived, highly proteinaceous PERT, each sample was assessed a second  
60 time in duplicate using a 1/10 dilution of the original extracted sample. Samples were deemed positive if either the primary or 1/10 dilution had HEV RNA detected with a RT-qPCR quantification cycle (Cq) value of  $\leq 42$ . All molecular primers used in the study are available in **Supplemental Table 1**. Both buffer extraction controls and RTqPCR negative control (reagents and water only) were run for each extraction batch and RTqPCR plate, respectively.

65

One step RT-digital PCR was done using the Absolute Q 1-step RT-dPCR Master Mix (Life Technologies Ca. A55146) according to manufactures instructions on the QuantStudio™ Absolute Q™ Digital PCR System (Applied Biosystems). In brief, 2.5  $\mu\text{l}$  4x master mix was mixed with 250 nM each primer and 400 nM probe used for RTqPCR [2] and added to a single  
70 tube where 1  $\mu\text{l}$  of extracted sample was added to a final volume of 10  $\mu\text{l}$ . Thereafter, 9  $\mu\text{l}$  of sample with master mix was added to one of 16 wells of the QuantStudio™ Absolute Q™ MAP16 plate, followed by 15  $\mu\text{l}$  of Absolute Q isolation buffer (A52730). Cycle conditions were as follows: reverse transcription 55°C for 10 minutes, 96°C for 10 minutes, 45 cycles of 96°C for 5 seconds and 60°C for 10 seconds. A negative template control (reagents and water only) and  
75 positive template control consisting of a 100 GC gBlock were also used for RTqPCR and ran on every plate. Samples negative on RTdPCR but positive on RTqPCR were repeated. Baseline threshold was set with negative control for each run. RTdPCR data was analysed on QuantStudio Absolute Q Digital PCR software version 6.

## 80 Use of an exogenous Positive Control - BCoV

Bovine coronavirus (BCoV) was used as an exogenous positive control. One step RTqPCR was performed to validate the BCoV spike (Calf Guard) using 5 µl of extracted samples with Taqman Fast virus 1-step master mix (Life Technologies Ca. 4444432), 200 nM primers and 125 nM probe as described previously [3] in a final volume of 20 µl. Tenfold dilutions starting at 5x10<sup>8</sup> to 50 GC of target gene in a plasmid were used for creating the standard curve. For each PERT extraction, a buffer blank with BCoV spike was assessed in parallel. Owing to the very high rates of PCR inhibitors in porcine derived PERT, each sample was assessed using both the original 5 µl of extracted sample, and a second 1/10 dilution performed in duplicate. The Cq of BCoV spiked buffer blank and BCoV spiked samples were compared for inhibitors. If the difference in Cq between spiked samples and buffer was >2 Cq, samples were considered to contain inhibitors as described previously.[4]

## Nested PCR and Sanger Sequencing of HEV RNA

### *Nested PCR-1:*

95 HEV *orf1* targeting the region **4228-4565 (Figure 2)** [5] is performed by the public health agency on all swine and human HEV samples from across Canada. In brief, extracted RNA was eluted into 50 µL and amplified using hemi-nested, broadly reactive primers. The final 337 bp amplicon product was purified and cycle sequenced using an Applied Biosystems 3730 XL DNA Analyzer (ThermoFisher Scientific, Mississauga, ON) with nested primers. The research lab employed the same nested PCR-1 as above to compare with public health sequence data. Reverse transcription was performed using Superscript IV (Life Technologies Ca.1809005) with 0.5 µl, 1 µl and 5 µl of extracted PERT capsule samples, using Random Hexamer primers (Life technology Ca.

N8080127) and RNaseOut in a 20 µl final volume. Nested PCR was performed on 2 µl cDNA using Platinum Taq polymerase (ThermoFisher Scientific Ca 15966025) as in Drexler, *et al* [5] in a 25 µl final volume on all sequenced samples for PCR-1 *orf1*. Nested PCR second reaction used the same conditions with 1 µl from the first PCR and primers for nested PCR second reaction. Samples were run on a 1% agarose gel and appropriate size bands were cut out and purified using the QIAquick gel purification kit (Qiagen Ca 28706). 60 ng gel purified sample and 5 pmol primer were used for Sanger sequencing.

110

#### *Nested PCR-2 and 3:*

Two different, additional targets were amplified using nested PCR for further verification. Nested PCR-2 (*orf2* [6] gene target 5622-5911) and PCR-3 (*orf1* [7] gene target 22-561) (**Figure 2**) on several samples were also PCR amplified with Phusion polymerase (Life Tech Ca. F630S) as per the manufacturer's instructions with 500 nM primers with cycles as described previously.[5-7]

115

#### **HEV RNA Genotyping**

Sequencing file traces were assessed and trimmed using Benchling (<https://www.benchling.com/>) and uploaded to the Hepatitis E Genotyping Tool (<https://www.rivm.nl/mpf/typingtool/hev/how-to-use>) as described previously.[8] All PERT HEV genotyping was performed under sterile conditions in the university research laboratory whereas all patient samples were sequenced in the in the National Microbiology Laboratory (with the exception of Case 2 which was sequenced in both). Phylogenetic analysis of output and

120

125 reference sequences was performed by maximum likelihood inference of a 315 bp trimmed *orf1*  
alignment using DIVEIN web tools [9] by the TN93+ $\gamma$ +I model.[10]

## **HEV Whole Genome Sequencing from PERT**

### ***Long Range PCR***

130 PERT was dissolved and RNA extracted as described in the main text. Concentrated samples  
were made pooling RNA extractions for 3 enzymes with 1 column each, final elution volume of  
150  $\mu$ L. A control using RNA from Patient 2 plasma was extracted using 400  $\mu$ L plasma and 800  
 $\mu$ L s for buffers with carrier RNA for the QIAamp MinElute Virus spin kit (Ca. 57705). RNA  
(0.5 to 5  $\mu$ L) was used to make cDNA with 50  $\mu$ M Oligo dT (Thermofisher Ca SO131) or 50 ng  
135 random hexamer primers (Thermofisher Ca.SO142) using Superscript IV (ThermoFisher Ca.  
18090050) as directed by the manufacture's instruction with RNAase out (ThermoFisher Ca  
10777019). Time and temperature for reverse transcription was modified to 60°C for 20 min as  
described previously.[11] Each round of Long Range PCR used nested PCR primers obtained  
from Papp *et al* [11] was carried out using Platinum™ SuperFi™ (ThermoFisher Ca.12351010 )  
140 IrPCR. Master mix was prepared using 5  $\mu$ L Superfi Buffer, 0.5  $\mu$ L 10mM dNTP's, 1  $\mu$ L 10  
 $\mu$ M of each primer, 1 to 2  $\mu$ L template, 5  $\mu$ L 5x GC enhancer and 0.25  $\mu$ L SuperFi™  
polymerases in a final volume of 25  $\mu$ L.[12] Cycle conditions were as follows: 95°C for 3min, 10  
cycles of 98°C for 10 seconds, 72°C decreasing by 1 degree per cycle for 10 seconds and 72°C  
for 4 minutes, 35 cycles of 98°C for 10 seconds, 68°C for 10 seconds and 72°C followed by 72°C  
145 for 8 minutes. PCR products were visualized on a 1% agarose gel stained with GelRed (Biotium,  
Fremont, CA. Ca. 41003) Bio-Rad ChemiDoc Touch. Primers used for sequencing are listed in  
***Supplemental Table 2.***

### ***Overlapping Primers***

150 RNA extractions and cDNA were made as above with all cDNA and RNA samples positive for Nested PCR tested. Platinum<sup>TM</sup> SuperFi<sup>TM</sup> (ThermoFisher Ca.12351010) polymerase was used with primers as described previously.[13] Master mix was prepared as described earlier. Cycle conditions were as follows: 95°C for 3 minutes with 10 cycles of 98°C for 15 seconds, 68°C and decreasing by one degree per cycle, 72°C for 1:30 minutes, followed by 35 cycles of 98°C for 15  
155 sec, 61°C for 10 sec, 72°C for 1:30 minutes with a final 72°C extension for 5 minutes. Samples were visualized on a 1% agarose gel stained with Gel Red on Bio-Rad ChemiDoc Touch. Primers used for sequencing are listed in ***Supplemental Table 2***.

### ***Direct cDNA Sequencing using a Nanopore Long-Read Approach***

160 PERT was dissolved and RNA extracted as described above. cDNA was synthesised as in the Oxford Nanopore protocol for ligation sequencing V14 – Direct cDNA sequencing (SDK-LSK114) after double stranded cDNA was prepared using switch strand primers, the Ligation sequencing amplicon – Native Barcoding Kit 24 V14 (SQK-NBD114.24) was used for barcoding and library preparation. The library was sequenced on the MinION flow cell FLO-MIN114 R10  
165 for a total of 43 hours. Primers used for sequencing are listed in ***Supplemental Table 2***.

### **Mitigation of PERT Matrix Interference**

The PERT matrix contains exceptionally high concentrations of enzymatically active proteins in each capsule with a range of active units including: protease, lipase, amylase, pH sensitive  
170 enteric coating, other pancreatic enzymes (i.e., RNase)[14] and other proprietary pharmaceutical



substances). To dissolve enterically coated capsules, several buffers were tested including 2% and 8% sodium bicarbonate, PBS (Phosphate buffered saline), 1M sodium acetate pH 7, TE (10mM Tris-HCl pH7.5, 1mM EDTA) and 0.1 M sodium phosphate (pH 8). Ultimately, 2% sodium bicarbonate and 0.1 M sodium phosphate (pH 8) were selected based on efficacy. We tested pH effects using 0.1M sodium phosphate buffer pH 6.8 and pH 8.0 on samples from two of the enterically coated PERT formulations. For RNA extractions, Trizol<sup>TM</sup> was used to circumvent enzymatically active protein rich substrate. Concentration of samples was done by pooling Trizol<sup>TM</sup> extractions into one Qiagen viral spin column. Attempts were made to concentrate and purify whole virions from PERT matrix using 100kDa ultrafiltration.[15] Ten PERT capsules from the same lot and manufacture were dissolved in 20 ml 2% sodium bicarbonate for one hour at room temperature followed by centrifugation at 4000 rpm for 30 minutes. The supernatant was then transferred to an ultracentrifuge tube and centrifuged at 20,000 rpm for 60 minutes. Following this, the supernatant was added to an Amicon or Centricon 100kDa concentrator (UFC710008) and centrifuged at 3000 rpm for up to 3 hours. Enterically coated samples were noted to clog filters with all applications with filtrate and concentrate volumes recorded. To attenuate concentrators from clogging, we attempted removal of enteric coating by precipitation at lower pH values. Enteric and non-enteric coated samples were dissolved in 2% sodium bicarbonate, spun down at 4000 rpm for 30 minutes followed by 20,000 rpm for 60 minutes with small aliquots of 1N HCl added. The pH was tested and any precipitate formation was recorded. Samples were then spun down again and filtered through 0.45  $\mu$ M filter and concentrated in 100kDa concentrators.

### **HEV Protein Assessment from PERT**

Samples were prepared as above to concentrated 10 PERT capsules. The concentrate was mixed  
195 1:1 with 50  $\mu$ L 2x Laemmli sample buffer +/- 200mM dithiothreitol (DTT), then heated at 95°C  
for 2 min. If samples were not heated the protein ladder degraded from active proteases in the  
PERT extracts. For SDS page, 5 to 15  $\mu$ L of sample was ran on 1mm thick 10-12% acrylamide  
gel. To prepare samples for mass spectrometry, 1 mm thick 10% SDS page gel was run for 30  
minutes at 150V with the section cut out between the top of ladder and ~60kDa (5mm by 5mm).  
200 The portion was then rinsed three times in ultra-pure water and stored at 4°C. Western blots were  
transfer from SDS-page method above, 5ul-15ul concentrate and filtrate of PERT concentrate  
samples were assessed. Multiple positive controls were attempted (each using plasma from Case  
2); PERT spiked with HEV plasma concentrate, buffer spiked with HEV plasma concentrate,  
confirmed HEV positive tissue culture supernatant. Negative controls utilized plasma from HEV  
205 seronegative individuals, 100mg/400ul PBS homogenized pork pancreas and negative tissue  
culture supernatant. Proteins on SDS page were transferred using Bio-Rad dry blotter 8min 2.5V  
in 1x Bio-Rad Trans-BlotTurbo Transfer buffer (Ca.10026938) to 0.45uM nitrocellulose. Blots  
were blocked in TBST (0.2M Tris pH 7.4, 1.5M NaCl<sub>2</sub>, 0.1% tween 20), 5% skim milk,  
overnight 4°C with rocking. Primary HEV Capsid ORF2 mouse antibody from Abcam (Ca.  
210 AB167453) and Sigma (Ca. MAB8002) were used at 1:1000 dilution in TBST, 5% skim milk,  
rotating for 1 hour at room temperature. This was followed by 3x washes in TBST for 10  
minutes each. Secondary anti mouse IgG HRP antibody (Abcam Ca. AB6789) was used at  
1:10000 dilution in TBST 5% milk and incubated for 1 hour at room temperature. The Blot was  
washed 3x in TBST for 10 min each. One mL of ECL reagent was mixed 1:1 (Sigma Ca.  
215 WBKLS0500) applied to blot and image on Chemi-Doc (Bio-Rad), as previously described.[16]

### HEV Cultivation from PERT by Cell Culture

Cell culture methods were adapted from Schemmerer *et al* [17] using the cell lines A549, HepG2 and HuH-7. Cell lines were cultured in BMEM (Eagle minimum essential medium [MEM])  
220 supplemented with 10% heat-inactivated fetal calf serum (FCS), 2 mM l-glutamine, 1% non-essential amino acids (NEAA), 100 U/mL penicillin G and 100 µg/mL streptomycin and MEMM (BMEM additionally supplemented with 2.5 µg/mL amphotericin B and 30 mM MgCl<sub>2</sub>). Cell cultures were seeded at concentrations of 10<sup>5</sup>/cm<sup>2</sup> viable cells in T25 flasks or 6 well plates in BMEM. Cell lines were then switched to MEMM and grown for 14 days prior to inoculation  
225 and cultured at 37°C with 5% CO<sub>2</sub>. HepG2 cells were inoculated with dissolved PERT from each manufacturer, positive plasma control and negative PBS buffer control. Samples were dissolved in 1 ml 2% sodium bicarbonate, vortexed and stirred with a sterile loop. PBS 0.2% BSA (Filter sterilized) was added and vortexed. Half of each sample was heated to 50°C for 5min and then vortexed followed by centrifugation at 8000 x g for 30 min. The supernatant was then  
230 filtered through a 0.45 to 0.2µm PES filter with media removed and 250 µL of inoculum including buffer control and positive plasma control added (filtered 0.2µM filter). These were then incubated at room temperature for 75 min. Thereafter, 2.5 ml of media was added and incubated at 34°C with 5% CO<sub>2</sub>. Media was completely refreshed at 24 hours and every 3-4 days thereafter. Supernatant was collected and RTqPCR was performed to check for positive tissue  
235 cultures. Cells were split on day 15 to check by immunofluorescence. A549, HepG2 and HuH-7 cell lines were inoculated with Dynabead Intact Virus enrichment from PERT and HEV positive plasma. Two PERT enzyme capsules from each manufacture were dissolved in 1 ml 2% sodium bicarb and then incubated for up to one hour followed by vortexing and once dissolved, addition of PBS (3 mL) was completed. A negative buffer control and a positive control containing 500

240  $\mu$ L positive patient plasma was added to the same buffers and extracted. Samples were spun  
down in 2 ml microfuge tubes at 8000xg for 30 min. Dynabead Intact Virus Enrichment  
(positively charged magnetic beads ThermoFisher Ca 10700D) manufactures protocol was  
followed and 80  $\mu$ L was added to the 4 ml PERT solution. Samples were incubated on a rotator  
for 10 minutes at room temperature then applied to a magnetic stand for 1 minute with  
245 supernatant removed. Dynabeads were rinsed with 1 ml PBS and mixed thoroughly, applied to a  
magnet for 1 minute with supernatant removed for up to two times or until beads were clear. To  
elute, 500  $\mu$ L release buffer (50mM Citric Acid, 50mM sodium phosphate) was added and  
incubated rotating for 10 min at room temperature. Samples were applied to a magnet for 1  
minute and the supernatant transferred to a new tube. The buffer was exchanged to PBS 0.2%  
250 BSA using a 10kDa concentrator to a final volume of 1500  $\mu$ L for infecting the 3 different cells  
lines. The media in the 6-well tissue culture plates was removed and 250  $\mu$ L extract per well was  
added for 75 minutes at room temperature. Media (2.5 mL) was added to wells and incubated at  
34.0°C with 5% CO<sub>2</sub>. The media was completely refreshed at 24 hours and every 3-4 days  
thereafter. Supernatant was collected and RTqPCR was performed to check for positive tissue  
255 culture. Cells were split on day 15 to check by immunofluorescence.

## SUPPLEMENTARY RESULTS

### HEV Serological Testing - ELISA Details

260 Twenty-three percent of samples (n=19/83) were positive via Abexxa, and 84% of samples  
(n=16/19) of these were confirmed positive with the Elab assay. Subjects with discordant HEV  
ELISA results were classified as seronegative.

### Assessment of PERT for Inhibition

265 We compared quantified BCoV between each spiked blank and the corresponding PERT and observed large discrepancies in cycles quantified, confirming high rates of PCR inhibitors in extracted PERT samples (*Supplemental Table 3*). As described by Ahmed and colleagues,[4] a delta  $C_q > 2$  between BCoV spiked sample and BCoV spiked buffer indicates presence of inhibitors. Indeed in our study, 71% of samples had a delta  $C_q \geq 2$  and  $C_q$  improved for most  
270 samples with a 1:10 dilution. Forty three percent (46/107; 43%) of samples  $C_q$  for BCoV improved with a 1 in 10 dilution. Twenty five percent (n=27/107; 25%) of samples had a  $C_q$  difference between the sample and the buffer spiked control of  $>10$ , suggesting high levels of PCR inhibition that may prevent HEV detection.[4]

### 275 Comparing HEV Quantification by RTqPCR and RT-dPCR

PERT samples assessed by RTqPCR worked best when diluted 1:10 as opposed to undiluted. These findings, along with the BCoV spike experiment, suggested the presence of inhibitors. Forty seven of 107 (47%) RTqPCR samples positive for HEV yielded a median 50 copies (cp)/capsule, IQR 23-160 cp/capsule and peak of 955 cp/capsule. For RTdPCR, 55 of 107 (51%)  
280 RNA samples were positive for HEV. Measuring with RTdPCR, there was a median of 165 cp/capsule, IQR 92-395 cp/capsule and peak of 5800 cp/capsule. Pearson's correlation between RTqPCR and RTdPCR was modest with  $r=0.7729$ ,  $P < 0.0001$  across 107 samples (*Supplemental Figure 3*). In total 64 of 107 samples were positive for HEV by either RTqPCR or RTdPCR. Thirty eight of 107 PERT capsules were positive for both RTqPCR and RTdPCR,  
285 whereas 9 of 107 samples were positive for only RTqPCR, and 17 of 107 samples were positive

for only RTdPCR. RTdPCR looks to out perform RTqPCR for these samples likely due to the low concentrations of target and high prevalence of inhibitors in samples. Digital PCR is thought to offer greater precision and copy number quantification due to it's binary nature.[18,19]

## 290 **Whole Genome Sequencing**

Despite efforts to perform amplicon based whole genome sequencing using long-range and overlapping HEV primers, we were unsuccessful in identifying HEV RNA by whole genome sequencing using PERT extracts. Three pooled PERT capsules from each of the four manufactures and the previous eight samples Sanger sequenced were unsuccessful with either  
295 method. Controls with positive patient HEV plasma (Case 2) were successful in generating overlapping PCR amplicons with had appropriate band sizes for all 8 amplicons spanning the HEV genome. No product was seen for PERT samples despite trying to adjust RNA, cDNA concentrations and adjusting cycle conditions. Bioanalysis at the UCalgary sequencing core facility of PERT extracted samples also indicated presence of inhibitors. To mitigate this, we  
300 attempted a second RNA clean up step, however, those samples were also unsuccessful. A review of the literature suggests the necessary template required for whole genome sequencing using serum, plasma or stool samples is  $10^5$  copies/ml,[11,13] whereas the highest PERT sample in our cohort did not exceed  $10^3$  copies/ml, suggesting limited template available for detection by WGS .

305

## **Protein Detection**

Concentration experiments using 100kDa ultrafiltration of 10 PERT capsules to retain viral particles and filter out concentrated smaller proteins protease, lipase and amylase had variable

results, in part due to pH sensitive enteric coating. Enterically coated enzymes, even after  
310 significant centrifugation, precipitated and clogged the filter, leading to poor concentration and  
flow through of smaller size proteins which was observed across all samples (i.e., manufacture -1  
concentrated 33-58%, manufacture-2 35-75%, manufacture-3 59-80% and manufacture-4 83-  
94%). SDS-page gels demonstrated the majority of proteins under 100kDa remained in the  
concentrated fraction instead of the intended filtrate. Despite the poor quality of the concentrate,  
315 Western blots for HEV ORF2 capsid protein were attempted but results inconclusive. Mass  
spectrometry was further attempted on subsequent samples without bands on Western Blots as  
original samples rapidly degraded. Results were of low yield for HEV proteins with only 3  
protein matches with one peptide each for the positive tissue culture supernatant spiked sample.

### 320 **Cell Culture**

Both culture experiments produced positive supernatant RTqPCR results for the positive control  
using patient plasma (Case 2) in all the cell lines tried. However, tissue culture supernatant from  
PERT treated samples were negative by RTqPCR for each of the two methods described above.  
More robust purification away from enzyme matrix and concentration of virions to a minimum  
325  $10^4$  cp/ml would be required in future experiments.[17]

Given the presumed infrequency with which replication competent HEV is expected to exist in  
PERT, ongoing efforts to cultivate it from PERT were deemed to be underpowered for detection.

330

## SUPPLEMENTAL FIGURES LEGEND

### Supplemental Figure 1: Study flowchart and design of cohorts evaluated for HEV

335 serostatus.

**Supplemental Figure 2: Clinical course of the three CF lung transplant recipients with chronic HEV infection.** The x-axis indicates number of days from first abnormal liver function testing. The left y-axis indicates the levels of liver function testing in either U/mL (AST, ALT, GGT, ALP) or  $\mu\text{mol}$  (Bilirubin total). The right y-axis indicates viral load (Altona Diagnostics RealStar HEV RT-PCR v2.0 assay, limit of detection of 0.20 IU/ul [95% CI: 0.12-0.45IU/ul]). Dotted black lines indicate the time of initial HEV serology positivity. Shaded regions indicate periods of time while cases were on treatment with ribavirin (RBV, light gray) or ribavirin and sofosbuvir (RBV + SOF, dark gray). Asterisks indicate that viral titres were not available during treatment period prior to becoming negative (serology was positive); thus, a mean viral titre was estimated and indicated by a dashed line for viral negativity (and to correspond with negative stool testing). AST: aspartate aminotransferase; ALT: alanine transaminase; GGT: gamma-glutamyl transferase; ALP: alkaline phosphatase; HEV: Hepatitis E Virus.

340  
345

350 **Supplemental Figure 3: Comparison of two different quantitative methods RTdPCR and RTqPCR for determining HEV RNA copies per PERT enzyme.** Pearson correlation  $r=0.7732$ ,  $R^2=0.5978$ ,  $P=<0.0001$ ,  $N=107$



**Supplementary Table 1: Primers and Probes Used for RTqPCR, RTdPCR and nested PCR**

Primer Name	Sequence	HEV Gene Target (nucleotide*)	Reference
HEVH-3329 F1	AGCTCCTGTACCTGATGTTGACTC	PCR-2 <i>orf2</i>  (5622-5911)*	Huang, <i>et al.</i> 2002 [6]
HEVH-3330 R1	CTACAGAGCGCCAGCCTTGATTGC		
HEVH-3331 F2	GCTCACGTCATCTGTCGCTGCTGG		
HEVH-3332 R2	GGGCTGAACCAAAATCCTGACATC		
HEVB1 E3_12S	ACGYATGTGGTTCGAWGCCATG	PCR-3 <i>orf1</i>  (22-561)***	Munoz-Chimeno, <i>et al.</i> 2016 [7]
HEVB1 E3_987A	AARAGCATRAGCCGRTCCCA		
HEVB1 E3_22S	TCGAWGCCATGGAGGCCCA		
HEVB1 E3_561A	GTCATCCCRTGICGRGCCAT		
HEV_R4565	CCGGGTTTCRCCIGAGTGTTCCTTCCA	PCR-1 <i>orf1</i>  (4228-4565)**	Drexler, <i>et al.</i> 2012 [5]
HEV_R4598	GCCATGTTCCAGAYGGTGTTCCA		
HEV_F4228	ACYTTYTGTGCYYTITTTGGTCCITGG TT		
HEV qPCR F	GGTGGTTTCTGGGGTGAC	<i>orf3</i>  (5311-5380)*	Salvio <i>et al.</i> 2018 [2]
HEV qPCR R	AGGGGTTGGTTGGATGAA		
HEVProbe FAM/BHQ1	TGATTCTCAGCCCTTCGC		
gBlock  Modified with buffer bases	GGTACCGAGAACCTGTA CTTCCAAT CCAATGACTGATGCTCAGT GAGTTA CTACGCAGTCACTCATAA TACGACT CACTATAGTTTCGTAGGGG TTGGTTG GATGAACGTAGCGAAGGG CTGAGA ATCAATGCGTGTACCCCA GAAAACC ACCTTCGTTATCTGGTGAT ACATGA ACAGATCCGTGCACCGTCA TTGGAA GTGGATAACGGATCCGAAT TCGA		
BCoV F	CTGGAAGTTGGTGGAGTT	Exogenous spiked control	Decaro <i>et al.</i> 2008 [20]
BCoV R	ATTATCGGCCTAACATACATC		
BCoV probe FAM/IBHQ	CCTTCATATCTATACACATCAAGTTG TT		

\*Sequence determined from GenBank accession number AF060669, \*\* GenBank accession number [NC\\_001434](#), \*\*\* reference #7

**Supplementary Table 2: Primers and Probes Used for HEV Whole Genome Sequencing**

Primer Name	Sequence	HEV Amplification Site	Reference
HEV 1 HEV-15_f	TGTGGTCGAYGCCATGGAG	15-1129	Wang <i>et al.</i> 2018 [13]
HEV 1 HEV-23_r	CRTCCTCAGAGGCRTTCC		
HEV 2 HEV-24_f	GCTGYTCACGGCTWATGAC	1034-2108	
HEV 2 HEV-16_r	AAKGGATTGGCMGACTCCC		
HEV 3 HEV-137_f	TCTAATGGCCTGGACTGTACTG	1894-3176	
HEV 3 HEV-124_r	TGGACCGAYGAGGCYCGCTGCAT		
HEV 4 HEV-123_f	AGGGTTGAGCAGAACCCYAAGAGG C	2602-3831	
HEV 4 HEV-18_r	CTGYTCAAGCTCTGGGCARG		
HEV 5 HEV-157_f	TACCACCAGCTKGCTGAGGAG	3751-4622	
HEV 5 HEV-41_r	GCCATGTTCCAGACDGTRTTCCA		
HEV 6 HEV-28_f	ATGGAGGAGTGTGGBATGC	4465-5332	
HEV 6 HEV-20_r	GAAGGGGTTGGTTGGATG		
HEV 7 HEV-126_f	TGCCTATGCTGCCCGGCCACC	5187-6325	
HEV 7 HEV-129_r	ACCYCCRGCCGACGAAATCAATTCT G		
HEV 8 HEV-05_f	CCGACAGAATTGATTTTCGTCGG	6297-7123	
HEV 8 HEV-22_r	CTCCCGRGTTTTACCYACCT		
lrPCR F	AGGCCCAAYCAGTTYATTAAGGCTCC TGGCATYACT	31	Papp <i>et al.</i> 2022 [11]
lrPCR R	CACACCCCTGCAAACCAAGRGC GCG RCACTCCGG	7,086	
Hemi-nested lrPCR R	CGGCACTCAGGGCAGAAATCATCRA AAGTRTGGG 7,063	7,063	
VN Primer	/5phos/ACTTGCCGTGCTGCTCTATCTTC TTTTTTTTTTTTTTTTTTTTTVN	--	Nanopore protocol Direct cDNA Sequencing V14 with SQK-LSK114
Strand-switching Primer	TTTCTGTTGGTGCTGATATTGCTmGm GmG		
PR2 Primer	/5Phos/TTTCTGTTGGTGCTGATATTG C		

**Supplementary Table 3: Pancreatic Enzyme Replacement Therapy Capsules Screened for HEV and Exogenous Spiked Control**

PERT Capsule			BCoV			HEV			
ID	Manufacturer, Lot, Bottle, Capsule	Formulation Strength	Blank with Spike Cq	Spike Cq	1/10 Dilution Spike Cq	Cq	1/10 Dilution Cq	RTqPCR cp/capsule	RTdPCR Cp/capsule
PE05	2-29-I-A	Low	24.62	ND*	29.7	ND	38.14	207.52	592.50
PE06	1-15-I-A	High	24.98	ND*	ND	ND	ND	0	0.00
PE07	2-27-I-A	High	25.12	ND*	29.22	ND	ND	0.00	0.00
PE08	1-19-I-A	High	26.02	41.5*	31.92	ND	39.79	160.01	110.00
PE09	1-7-I-A	High	26.02	32.77*	29.26	ND	ND	0.00	226.67
PE10	4-38-I-A	High	25.12	ND*	ND	ND	ND	0.00	0.00
PE11	1-8-I-A	High	24.62	ND*	ND	ND	ND	0.00	0.00
PE12	2-30-I-A	Low	25.12	30.46*	29.13	ND	ND	0.00	0.00
PE13	1-20-I-A	High	25.12	42.49*	ND	ND	ND	0.00	0.00
PE14	1-2-I-A	Low	24.77	24.77	33.21	ND	ND	0.00	0.00
PE15	1-9-I-A	High	24.49	27*	29.68	42.06	43.22	20.57	275.00
PE16	1-10-I-A	High	24.34	27.86*	30.26	42.7	41.41	73.04	275.00
PE17	1-21-I-A	High	24.62	41.27	34.85	ND	40.29	125.68	792
PE18	4-39-I-A	High	24.62	36.94*	29.44	ND	ND	0.00	0.00
PE19	1-11-I-A	High	27.28	ND*	ND	ND	ND	0.00	0.00
PE20	1-12-I-A	High	24.62	ND*	ND	ND	ND	0.00	0.00
PE21	1-13-I-A	High	27.28	ND*	ND	ND	ND	0.00	0.00
PE22	1-16-I-A	High	25.12	39.91*	31.63	ND	40.51	108.50	460.00
PE22-2	2-26-IA	High	24.76	ND*	37.34	ND	ND	0.00	450.00
PE23	2-41-I-A	Low	24.76	38.32*	ND	ND	ND	0.00	0.00
PE24	1-42-I-A	Low	24.83	34.42*	35.9	ND	ND	0.00	0.00
PE25	1-14-I-A	High	26.02	28.49*	29.11	44	40.54	62.13	73.33
PE27	1-4-II-A	High	24.69	34.18*	ND	ND	ND	0.00	165.00
PE28	1-4-II-B	High	24.89	34.21*	ND	ND	ND	0.00	165.00
PE29	1-4-II-C	High	26.02	ND*	ND	ND	ND	0.00	0.00

PE31	1-4-I-A	High	24.96	29.53*	28.99	ND	ND	0.00	137.50
PE32	1-4-I-B	High	25.22	28.4*	29.91	ND	ND	0.00	137.50
PE33	2-24-I-A	High	25.22	26.29	28.77	38.38	37.64	476.82	4237.50
PE35	1-4-I-C	High	25.08	26.34	28.79	44.66	ND	0.00	137.50
PE36	2-24-I-B	High	25.08	26.78	28.77	39.4	38.04	363.52	5800.00
PE37	2-24-I-C	High	24.15	25.73	28.04	38.08	38.14	535.83	4870.00
PE38-39	2-24-I-DE	High	24.15	27.64*	26.95	42.76	36.16	955.32	3000.00
PE40	1-3-I-A	High	26.02	35.91*	29.59	ND	ND	0.00	91.67
PE41	1-4-II-C	High	26.02	33.51*	29.38	ND	ND	0.00	0.00
PE42	4-36-I-A	High	24.84	ND*	30.5	ND	ND	0.00	0.00
PE43	4-36-I-B	High	26.02	36.53*	27.84	ND	ND	0.00	0.00
PE44	2-40-I-D	Low	24.87	30.22*	28.75	ND	ND	0.00	0.00
PE45	2-40-I-E	Low	24.84	38.66*	36.38	ND	ND	0.00	0.00
PE46	2-40-I-F	Low	26.02	29.28*	29.08	ND	ND	0.00	0.00
PE47	4-36-I-C	High	24.87	ND*	32.21	ND	ND	0.00	0.00
PE48-49	1-4-II-DE	High	25.92	38.16*	29.48	ND	ND	0.00	27.50
PE50-51	1-3-I-BC	High	27.02	25.92	30.9	ND	40.15	14.95	197.50
PE52-53	1-4-I-DE	High	30.44	25.92	30.34	ND	41.89	4.57	27.50
PE54	4-36-II-A	High	24.83	30.5*	30.19	ND	ND	0.00	0.00
PE55	4-36-II-B	High	24.83	32.45*	30.29	ND	ND	0.00	170.00
PE56	2-24-I-F	High	23.86	25.99*	28.6	35.74	36.49	422.16	2490.00
PE61	1-4-I-F	High	32.417	28.147	41.21	40.34	38.6	477.00	0.00
PE67	2-25-I-A	High	26.95	36.38*	38.91	ND	38.14	428.25	1360.00
PE68	2-25-I-B	High	26.95	35.6*	39.02	38.43	38.11	585.72	3420.00
PE69	2-22-I-A	High	24.57	30.46*	28.42	ND	41.27	27.54	99.00
PE70	2-22-I-B	High	24.57	35.55*	28.91	ND	ND	0.00	0.00
PE71	2-22-I-C	High	24.57	34.64*	28.85	ND	ND	0.00	110.00
PE72	2-22-I-D	High	24.57	29.9*	28.54	ND	ND	0.00	0.00
PE73	2-22-I-E	High	24.57	31.2*	28.44	ND	ND	0.00	110.00
PE74	1-5-I-A	High	30.56	27.06	28.51	ND	ND	0.00	230.00
PE75	1-5-I-B	High	30.56	31.93	28.84	ND	41.19	34.89	110.00
PE76	1-5-I-C	High	30.56	25.59	28.12	ND	41.85	22.51	0.00

PE77	1-5-I-D	High	30.56	26.84	28.74	44.74	40.67	49.67	340.00
PE78	1-5-I-E	High	30.56	27.06	28.76	ND	ND	0.00	0.00
PE79	3-34-I-A	Low	24.83	24.38	27.1	41.72	ND	1.23	55.00
PE80	3-34-I-B	Low	24.83	27.92*	27.91	ND	ND	0.00	0.00
PE81	3-34-I-C	Low	24.83	25.47	27.25	ND	ND	0.00	0.00
PE82	3-34-I-D	Low	24.83	24.77	27.33	44.83	ND	0.00	55.00
PE83	3-34-I-E	Low	24.83	25.13	27.33	ND	ND	0.00	0.00
PE84	3-31-I-A	Low	24.83	29.15*	28.01	ND	ND	0.00	0.00
PE85	3-31-I-B	Low	24.83	25.11	27.35	ND	41.07	30.42	115.00
PE86	3-31-I-C	Low	24.83	26.28	27.23	ND	ND	0.00	170.00
PE87	3-31-I-D	Low	24.83	25.37	27.37	ND	41.77	24.98	55.00
PE88	3-31-I-E	Low	24.83	26.61	27.3	ND	39.49	83.44	55.00
PE89	3-32-I-A	High	25.13	33.57*	30.42	ND	ND	0.00	0.00
PE90	3-32-I-B	High	25.13	26.6	30.03	ND	40.84	42.41	0.00
PE91	3-32-I-C	High	25.13	26.35	29.09	40.07	41.84	19.60	0.00
PE92	3-32-I-D	High	25.13	26.12	29.55	40.1	39.14	123.98	0.00
PE93	3-32-I-E	High	25.13	28.55*	29.31	44.86	40.02	66.26	110.00
PE94	2-28-I-A	Low	30.56	26.58	29.24	39.02	40.87	18.41	55.00
PE95	2-28-I-B	Low	30.56	27.87	28.64	ND	39.49	53.99	55.00
PE96	2-28-I-C	Low	30.56	28.85	29.72	ND	41.64	10.75	110.00
PE97	2-28-I-D	Low	30.56	26.11	27.27	38.41	37.3	329.82	285.00
PE98	2-28-I-E	Low	30.56	25.56	27.56	ND	36.97	275.89	735.00
PE99	2-23-I-E	High	25.13	29.24*	28.74	ND	39.82	86.64	230.00
PE100	2-23-I-A	High	25.13	30.54*	29.06	ND	41.48	2.21	46.00
PE101	2-23-I-B	High	25.13	32.87*	28.87	ND	40.72	40.73	230.00
PE102	2-23-I-C	High	25.13	31.53*	28.77	ND	40.91	56.21	110.00
PE103	2-23-I-D	High	25.13	31.04*	29.35	ND	40.4	50.23	230.00
PE104	1-1-I-A	Low	24.83	28.95*	28.63	ND	ND	0.00	0.00
PE105	1-1-I-B	Low	24.83	28.94*	28.54	ND	ND	0.00	0.00
PE106	1-1-I-C	Low	24.83	32.64*	29.59	ND	ND	0.00	0.00
PE107	1-1-I-D	Low	24.83	28.77*	28.51	ND	ND	0.00	0.00
PE108	1-1-I-E	Low	24.83	27.42*	28.49	ND	ND	0.00	0.00

PE109	3-32-II-A	High	23.86	25.56	29.01	38.9	41.93	10.00	55.00
PE110	3-32-II-B	High	23.86	27.09*	30.08	39.91	39.99	38.45	395.00
PE111	3-32-II-C	Low	23.86	28.44*	30.82	ND	ND	0.00	0.00
PE112	3-32-II-D	High	23.86	26.71*	30.01	40.21	ND	3.26	11.00
PE113	3-32-II-E	High	23.86	28.19*	30.23	42.37	40.53	26.26	11.00
PE114	2-40-I-A	Low	24.83	32.92*	28.69	ND	ND	0.00	565.00
PE115	2-40-I-B	Low	24.83	34.28*	34.51	ND	ND	0.00	0.00
PE116	2-40-I-C	Low	24.78	36.91*	36.03	ND	ND	0.00	0.00
PE117	4-35-I-A	Low	24.78	29.18*	30.86	ND	ND	0.00	0.00
PE118	4-35-I-B	Low	24.78	29.94*	31.01	ND	ND	0.00	0.00
PE119	4-35-I-C	Low	24.78	30.21*	30.67	ND	ND	0.00	0.00
PE120	4-35-I-D	Low	24.78	30.77*	30.91	ND	ND	0.00	0.00
PE121	4-35-I-E	Low	24.78	29.15*	31.39	41.89	41.35	22.35	0.00
PE122	4-37-I-A	High	24.78	27.16*	29.54	ND	39.68	47.06	340.00
PE123	4-37-I-B	High	24.78	36.82*	31.68	ND	40.89	20.45	0.00
PE124	4-37-I-C	High	24.78	34.04*	32.91	ND	40.08	35.65	0.00
PE125	4-37-I-D	High	24.78	44.03*	33.62	ND	40.75	22.53	0.00
PE126	4-37-I-E	High	24.78	ND*	32.2	ND	ND	0.00	0.00

Canadian PERT Manufactures are coded as 1-4.

PERT capsule strength are coded as low  $\leq 10,000$  units of lipase and high  $> 10,000$  units of lipase.

ND = Not determined, Cq= Cycle of Quantification.

\*Indicates presence of inhibitors as noted by an increase Cq  $> 2$  for spiked sample compared to spiked buffer.

## References

1. Boullata AM, Boullata JI. Pancreatic enzymes prepared in bicarbonate solution for administration through enteral feeding tubes. *Am J Health Syst Pharm* 2015;72(14):1210-4. doi: 10.2146/ajhp140611 [published Online First: 2015/07/08]
2. Salvio AL, Lopes AO, Almeida AJ, et al. Detection and quantification of hepatitis E virus in the absence of IgG and IgM anti-HEV in HIV-positive patients. *J Appl Microbiol* 2018;125(4):1208-15. doi: 10.1111/jam.14024 [published Online First: 2018/06/20]
3. Acosta N, Bautista MA, Hollman J, et al. A multicenter study investigating SARS-CoV-2 in tertiary-care hospital wastewater. viral burden correlates with increasing hospitalized cases as well as hospital-associated transmissions and outbreaks. *Water Res* 2021;201:117369. doi: 10.1016/j.watres.2021.117369 [published Online First: 2021/07/07]
4. Ahmed W, Bertsch PM, Bivins A, et al. Comparison of virus concentration methods for the RT-qPCR-based recovery of murine hepatitis virus, a surrogate for SARS-CoV-2 from untreated wastewater. *Sci Total Environ* 2020;739:139960. doi: 10.1016/j.scitotenv.2020.139960 [published Online First: 20200605]
5. Drexler JF, Seelen A, Corman VM, et al. Bats worldwide carry hepatitis E virus-related viruses that form a putative novel genus within the family Hepeviridae. *J Virol* 2012;86(17):9134-47. doi: 10.1128/JVI.00800-12 [published Online First: 20120613]
6. Huang FF, Haqshenas G, Guenette DK, et al. Detection by reverse transcription-PCR and genetic characterization of field isolates of swine hepatitis E virus from pigs in different geographic regions of the United States. *J Clin Microbiol* 2002;40(4):1326-32. doi: 10.1128/JCM.40.4.1326-1332.2002 [published Online First: 2002/03/30]

7. Munoz-Chimeno M, Forero JE, Echevarria JM, et al. Full coding hepatitis E virus genotype 3 genome amplification method. *J Virol Methods* 2016;230:18-23. doi: 10.1016/j.jviromet.2016.01.004 [published Online First: 2016/01/20]
8. Bigoraj E, Paszkiewicz W, Rzezutka A. Porcine Blood and Liver as Sporadic Sources of Hepatitis E Virus (HEV) in the Production Chain of Offal-Derived Foodstuffs in Poland. *Food Environ Virol* 2021;13(3):347-56. doi: 10.1007/s12560-021-09475-z [published Online First: 2021/04/24]
9. Deng W, Maust BS, Nickle DC, et al. DIVEIN: a web server to analyze phylogenies, sequence divergence, diversity, and informative sites. *Biotechniques* 2010;48(5):405-8. doi: 10.2144/000113370
10. Guindon S, Dufayard JF, Lefort V, et al. New algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3.0. *Syst Biol* 2010;59(3):307-21. doi: 10.1093/sysbio/syq010 [published Online First: 20100329]
11. Papp CP, Biedermann P, Harms D, et al. Advanced sequencing approaches detected insertions of viral and human origin in the viral genome of chronic hepatitis E virus patients. *Sci Rep* 2022;12(1):1720. doi: 10.1038/s41598-022-05706-w [published Online First: 20220202]
12. Asif K, O'Rourke D, Sabir AJ, et al. Characterisation of the whole genome sequence of an avian hepatitis E virus directly from clinical specimens reveals possible recombination events between European and USA strains. *Infect Genet Evol* 2021;96:105095. doi: 10.1016/j.meegid.2021.105095 [published Online First: 20210929]



13. Wang B, Harms D, Papp CP, et al. Comprehensive Molecular Approach for Characterization of Hepatitis E Virus Genotype 3 Variants. *J Clin Microbiol* 2018;56(5) doi: 10.1128/JCM.01686-17 [published Online First: 20180425]
14. Jackson RL, Hirs CH. The primary structure of porcine pancreatic ribonuclease. I. The distribution and sites of carbohydrate attachment. *J Biol Chem* 1970;245(3):624-36.
15. Croci L, Dubois E, Cook N, et al. Current Methods for Extraction and Concentration of Enteric Viruses from Fresh Fruit and Vegetables: Towards International Standards. *Food Analytical Methods* 2008;1(2):73-84. doi: 10.1007/s12161-008-9025-4
16. Yin X, Ying D, Lhomme S, et al. Origin, antigenicity, and function of a secreted form of ORF2 in hepatitis E virus infection. *Proc Natl Acad Sci U S A* 2018;115(18):4773-78. doi: 10.1073/pnas.1721345115 [published Online First: 20180418]
17. Schemmerer M, Johne R, Erl M, et al. Isolation of Subtype 3c, 3e and 3f-Like Hepatitis E Virus Strains Stably Replicating to High Viral Loads in an Optimized Cell Culture System. *Viruses* 2019;11(6) doi: 10.3390/v11060483 [published Online First: 20190528]
18. d MG, Huggett JF. The Digital MIQE Guidelines Update: Minimum Information for Publication of Quantitative Digital PCR Experiments for 2020. *Clin Chem* 2020;66(8):1012-29. doi: 10.1093/clinchem/hvaa125 [published Online First: 2020/08/04]
19. Ahmed W, Smith WJM, Metcalfe S, et al. Comparison of RT-qPCR and RT-dPCR Platforms for the Trace Detection of SARS-CoV-2 RNA in Wastewater. *ACS ES T Water* 2022;2(11):1871-80. doi: 10.1021/acsestwater.1c00387 [published Online First: 2022/11/17]

20. Decaro N, Elia G, Campolo M, et al. Detection of bovine coronavirus using a TaqMan-based real-time RT-PCR assay. *J Virol Methods* 2008;151(2):167-71. doi: 10.1016/j.jviromet.2008.05.016 [published Online First: 2008/06/27]

